- Home
- CRDF vs INMB Comparison
CRDF vs INMB Comparison
Compare CRDF & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- INMB
- Stock Information
- Founded
- CRDF 1999
- INMB 2015
- Country
- CRDF United States
- INMB United States
- Employees
- CRDF N/A
- INMB N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- CRDF Health Care
- INMB Health Care
- Exchange
- CRDF Nasdaq
- INMB Nasdaq
- Market Cap
- CRDF 288.7M
- INMB 203.5M
- IPO Year
- CRDF N/A
- INMB 2019
- Fundamental
- Price
- CRDF $4.19
- INMB $8.69
- Analyst Decision
- CRDF Strong Buy
- INMB Strong Buy
- Analyst Count
- CRDF 4
- INMB 3
- Target Price
- CRDF $12.00
- INMB $24.33
- AVG Volume (30 Days)
- CRDF 1.1M
- INMB 290.5K
- Earning Date
- CRDF 05-01-2025
- INMB 03-27-2025
- Dividend Yield
- CRDF N/A
- INMB N/A
- EPS Growth
- CRDF N/A
- INMB N/A
- EPS
- CRDF N/A
- INMB N/A
- Revenue
- CRDF $683,000.00
- INMB $42,000.00
- Revenue This Year
- CRDF N/A
- INMB N/A
- Revenue Next Year
- CRDF N/A
- INMB N/A
- P/E Ratio
- CRDF N/A
- INMB N/A
- Revenue Growth
- CRDF 39.96
- INMB N/A
- 52 Week Low
- CRDF $2.01
- INMB $4.32
- 52 Week High
- CRDF $6.42
- INMB $12.72
- Technical
- Relative Strength Index (RSI)
- CRDF 48.00
- INMB 51.16
- Support Level
- CRDF $3.52
- INMB $7.79
- Resistance Level
- CRDF $4.31
- INMB $8.35
- Average True Range (ATR)
- CRDF 0.36
- INMB 0.55
- MACD
- CRDF -0.07
- INMB -0.08
- Stochastic Oscillator
- CRDF 28.57
- INMB 48.72
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.